Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy

Sponsor
University of Saskatchewan (Other)
Overall Status
Completed
CT.gov ID
NCT02987985
Collaborator
(none)
50
1
2
38.2
1.3

Study Details

Study Description

Brief Summary

The objective of this trial is to determine whether an opioid-free general anesthetic (OFA) technique utilizing ketamine, dexmedetomidine, lidocaine, and gabapentin can help reduce postoperative respiratory depression in the post-anesthesia care unit and ward in children with sleep-disordered breathing undergoing tonsillectomy when compared with traditional opioid-containing techniques. It is expected that this OFA regimen will have a measurable reduction on postoperative respiratory depression in children with sleep-disordered breathing.

Condition or Disease Intervention/Treatment Phase
  • Drug: Acetaminophen, gabapentin
  • Drug: Acetaminophen
  • Drug: Ketamine , Lidocaine , Dexmedetomidine
  • Drug: Fentanyl, Dexmedetomidine
  • Drug: Dexamethasone , Ondansetron
  • Drug: Sevoflurane
  • Drug: Sevoflurane, Fentanyl
Phase 3

Detailed Description

The objective of this trial is to determine whether an opioid-free general anesthetic can help reduce postoperative respiratory depression in the post-anesthesia care unit and ward in children with sleep-disordered breathing undergoing tonsillectomy when compared with traditional opioid-containing techniques.

Study Design

Study Type:
Interventional
Actual Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy: a Pilot Study
Actual Study Start Date :
Oct 15, 2017
Actual Primary Completion Date :
Sep 20, 2019
Actual Study Completion Date :
Dec 20, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Opioid-free anesthesia

Opioid-free preoperative medications, Opioid-free pre-intubation medications, Opioid-free maintenance medication, postoperative nausea and vomiting prophylaxis

Drug: Acetaminophen, gabapentin
acetaminophen 15 mg/kg, gabapentin 10 mg/kg
Other Names:
  • Opioid-free preoperative medications
  • Drug: Ketamine , Lidocaine , Dexmedetomidine
    Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
    Other Names:
  • Opioid-free pre-intubation medications
  • Drug: Dexamethasone , Ondansetron
    Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
    Other Names:
  • Postoperative nausea and vomiting prophylaxis
  • Drug: Sevoflurane
    Sevoflurane (dose titrated to effect)
    Other Names:
  • Opioid-free maintenance medication
  • Active Comparator: Opioid-sparing anesthesia

    Opioid-sparing preoperative medications, Opioid sparing pre-intubation medications, Opioid-sparing maintenance medications, postoperative nausea and vomiting prophylaxis

    Drug: Acetaminophen
    acetaminophen 15 mg/kg
    Other Names:
  • Opioid-sparing preoperative medications
  • Drug: Fentanyl, Dexmedetomidine
    Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
    Other Names:
  • Opioid sparing pre-intubation medications
  • Drug: Dexamethasone , Ondansetron
    Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
    Other Names:
  • Postoperative nausea and vomiting prophylaxis
  • Drug: Sevoflurane, Fentanyl
    Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
    Other Names:
  • Opioid-sparing maintenance medications
  • Outcome Measures

    Primary Outcome Measures

    1. Respiratory depression [24 hours following surgery]

      Number of desaturation events (oxygen saturation by pulse oximetry (SPO2) <90%) as measured by a Masimo Radical-7 pulse oximeter during the first postoperative night's sleep

    Secondary Outcome Measures

    1. Quantified opioid consumption [24 hours following surgery]

      Quantified opioid consumption

    2. Pediatric Agitation Emergence Delirium (PAED) scale [24 hours following surgery]

      Pediatric Agitation Emergence Delirium (PAED) scale

    3. Face Legs Activity Cry Consolability (FLACC) scale [24 hours following surgery]

      Face Legs Activity Cry Consolability (FLACC) scale

    4. Time until Post Anesthesia Care Unit (PACU) discharge readiness [24 hours following surgery]

      Time until Post Anesthesia Care Unit (PACU) discharge readiness

    5. Other adverse effects [24 hours following surgery]

      Other adverse effects

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A to 12 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients aged 0-12 years with Sleep Disordered Breathing (SDB) who are scheduled for elective Tonsillectomy/AdenoTonsillectomy (T/AT) will be recruited at Royal University Hospital, Saskatoon, Saskatchewan.
    Exclusion Criteria:
    • age > 12; American Society of Anesthesiologists (ASA) Classification > IV; significant cardiorespiratory, neurological, craniofacial, hepatic, renal, or genetic disorders, excluding SDB; concomitant surgical procedures other than myringotomy and tubes; and allergy to any of the study drugs

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Royal University Hospital Saskatoon Saskatchewan Canada S7N 0W8

    Sponsors and Collaborators

    • University of Saskatchewan

    Investigators

    • Principal Investigator: Jon Gamble, MD, University of Saskatchewan

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jonathan Gamble, Principle Investigator, University of Saskatchewan
    ClinicalTrials.gov Identifier:
    NCT02987985
    Other Study ID Numbers:
    • BIO 16-255
    First Posted:
    Dec 9, 2016
    Last Update Posted:
    Aug 10, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Jonathan Gamble, Principle Investigator, University of Saskatchewan
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 10, 2021